Crizotinib | List of Frontiers open access articles

Case Report

Published on 24 Jul 2023

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report

in Thoracic Oncology

Jiantao Wang
Wenqing Yao
Weiya Wang
Mingyu Fan
Kaili Huang
Zhenkun Liu
Daxing Zhu

Frontiers in Oncology

doi 10.3389/fonc.2023.1164543

3,151 views
3 citations

Mini Review

Published on 14 Oct 2021

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

in Pharmacology of Anti-Cancer Drugs

Jinchun Wu
Yongbin Hu
Omar Abdihamid
Gengwen Huang
Sheng Xiao
Bin Li

Frontiers in Oncology

doi 10.3389/fonc.2021.684865

5,217 views
7 citations

Case Report

Published on 20 Sep 2022

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

in Cancer Molecular Targets and Therapeutics

Chuangzhou Rao
Liangqin Nie
Xiaokang Wu
Xiaobo Miao
Ting Chen
Liuxi Chen
Dongqing Zhang
Quan Lin

Frontiers in Oncology

doi 10.3389/fonc.2022.915502

2,466 views
2 citations

Original Research

Published on 12 May 2020

Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro

in Pharmacology of Anti-Cancer Drugs

Kyeong Seok Kim
Chunxue Jiang
Ji Young Kim
Jae Hyeon Park
Hae Ri Kim
Su Hyun Lee
Hyung Sik Kim
Sungpil Yoon

Frontiers in Oncology

doi 10.3389/fonc.2020.00696

5,565 views
17 citations

Case Report

Accepted on 12 Feb 2026

Case Report: Pregnant ROS1+ Lung Cancer Patient Treated with Crizotinib: Impact on Infancy

in Thoracic Oncology

Theresa Weber
Jörg Hoffmann
Christian Michel
Andreas Burchert
Jelena Pesek
R. Verena Taudte
Katharina Schoner
Hilda Bartos
Simon Viniol
Paul Weiland

Frontiers in Oncology

Case Report

Accepted on 20 Feb 2026

Case Report: TPR-ALK Fusion-Positive Inflammatory Myofibroblastic Tumour Treated with Sequential ALK Inhibitors

in Thoracic Oncology

Fabiano Flauto
Filippo Vitale
Caterina De Luca
Rosa Maria Di Crescenzo
Francesco Petteruti
Annarita Peddio
Giuseppe Neola
Vincenzo Damiano

Frontiers in Oncology

Original Research

Published on 01 Feb 2021

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Lin Guo
Hui Gong
Ting-Li Tang
Bi-Kui Zhang
Lei-Yi Zhang
Miao Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2021.620934

7,750 views
41 citations

Original Research

Published on 22 Oct 2019

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center

in Thoracic Oncology

Chang Liu
Hui Yu
Qianqian Long
Haiquan Chen
Yuan Li
Weixin Zhao
Kuaile Zhao
Zhengfei Zhu
Si Sun
Min Fan

Frontiers in Oncology

doi 10.3389/fonc.2019.01116

6,756 views
22 citations

Mini Review

Published on 30 Nov 2016

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

in Pathology

Phu N. Tran
Samuel J. Klempner

Frontiers in Medicine

doi 10.3389/fmed.2016.00065

8,640 views
10 citations

Case Report

Published on 18 Oct 2022

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

in Thoracic Oncology

Woo Kyung Ryu
Hyungkeun Cha
Mi Hwa Park
Jung Soo Kim
Jeong-Seok Choi
Lucia Kim
Kyung-Hee Lee
Hae-Seong Nam

Frontiers in Oncology

doi 10.3389/fonc.2022.900966

3,478 views
3 citations

Case Report

Published on 07 Jul 2022

Renal Abscess Caused by Crizotinib: A Rare Case Report

in Cancer Molecular Targets and Therapeutics

Zhaojun Wan
Kai Wang
Xiangfu Yin
Xiangting Guo
Guoli Cheng
Jihong Pan

Frontiers in Oncology

doi 10.3389/fonc.2022.920990

2,671 views
4 citations

Original Research

Published on 25 Nov 2020

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

in Cancer Immunity and Immunotherapy

Liangliang Cai
Jianchun Duan
Li Qian
Zhijie Wang
Shuhang Wang
Sini Li
Chao Wang
Jie Zhao
Xue Zhang
Hua Bai

Frontiers in Immunology

doi 10.3389/fimmu.2020.527750

8,113 views
12 citations

Mini Review

Published on 21 Jul 2014

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

in Thoracic Oncology

Khashayar Esfahani
Jason Scott Agulnik
Victor Cohen

Frontiers in Oncology

doi 10.3389/fonc.2014.00174

10,921 views
25 citations

Case Report

Published on 16 Apr 2024

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion

in Thoracic Oncology

Su-Su Dong
Wen Dong
Ya-Fen Tan
Qiang Xiao
Tian-Li Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1370901

2,261 views
3 citations

Review

Published on 01 Apr 2014

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

in Pharmacology of Anti-Cancer Drugs

Sai-Hong Ignatius Ou

Frontiers in Oncology

doi 10.3389/fonc.2014.00058

14,799 views
24 citations

Original Research

Published on 28 May 2021

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

SiNi Li
JianHe Li
LiuBao Peng
YaMin Li
XiaoMin Wan

Frontiers in Oncology

doi 10.3389/fonc.2021.684073

9,442 views
15 citations

Articles

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro

Case Report: Pregnant ROS1+ Lung Cancer Patient Treated with Crizotinib: Impact on Infancy

Case Report: TPR-ALK Fusion-Positive Inflammatory Myofibroblastic Tumour Treated with Sequential ALK Inhibitors

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Renal Abscess Caused by Crizotinib: A Rare Case Report

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer